Details of the Drug Reposition

General Information of This Drug (ID: DMM549D)

Drug Name
IMO-3100   DMM549D

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psoriasis vulgaris DIS6M7AN EA90 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Autoimmune diabetes DISW6UF1 5A10 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01622348) Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).